The Emerging Role of Fibrate Therapy in Reducing Cardiovascular Risk in Patients with Diabetes

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:
This CME-certified monograph is intended for cardiologists and primary care physicians.

Upon completing this activity, you should be able to:

• Discuss appropriate pharmacologic treatment options to reduce cardiovascular risk in patients with diabetes.
• Discuss the safety and efficacy of statin and fibrate combination therapy in reducing cardiovascular events in patients with diabetes.
• Discuss the micro- and macrovascular benefits of fibrate therapy demonstrated in the FIELD study.

Accreditation:
Millennium CME Institute, Inc., proudly acknowledges its academic partnership with the UMDNJ—Center for Continuing and Outreach Education in the development of this activity and in the review of the educational content. Millennium CME Institute, Inc., has assumed the responsibility for long-term retention of individual credit records.

Millennium CME Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Millennium CME Institute, Inc., designates this educational activity for a maximum of 1.5 Category 1 Credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity was prepared in accordance with the ACCME Essentials.

This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by John B. Kostis, MD, FACC, FACP; Liliana Cohen, MD; Anthony J. Messina, MD; and Pirouz Parang, MD.

Release Date: April 2006

Expiration Date: April 30, 2007

© 2005 Millennium CME Institute, Inc. and UMDNJ—Center for Continuing and Outreach Education

Faculty Disclosure:
Millennium CME Institute, Inc., endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. All faculty are required to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations and with companies who have provided the commercial support for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The faculty listed below have declared that they have no financial arrangements or affiliations with any corporate organization offering financial support or grant monies for this CME program or with any corporate organization whose product(s) will be discussed in their presentation(s):

• Liliana Cohen, MD
• David C. Howard
• Anthony J. Messina, MD
• Pirouz Parang, MD
• Tim Robinson
• John Warren

The faculty listed below have declared the following arrangements and/or affiliations:

David G. Robertson, MD: Honoraria—Abbott, AstraZeneca, Bristol-Myers Squibb, Kos, Pfizer; Grant/Research Support—AstraZeneca, Kos, Pfizer

John B. Kostis, MD, FACC, FACP: Grant/Research Support—Pfizer; Speakers Bureau—AstraZeneca, Aventis, BMS, Merck, Pfizer, Sankyo; Consultant—Berlex, Forest Labs, Pfizer, Sankyo, Schering-Plough, Taisho; Scientific Board Member—Pfizer, Schering-Plough

Signed Disclosure forms are on file at Millennium CME Institute, Inc.

The opinions expressed in this publication are those of the participating faculty and do not necessarily reflect the opinions or the recommendations of their affiliated institutions; University of Medicine & Dentistry of New Jersey; Millennium CME Institute, Inc.; or any other persons. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this publication should not be used by clinicians without evaluation of their patients’ conditions, assessment of possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with the recommendations of other authorities.

This Cardiology Forum Report^TM was made possible through an unrestricted educational grant from Abbott.

This CME-certified monograph does not contain information on commercial products that is outside of current FDA-approved labeling or information on the investigational use of products not yet approved by the FDA.

Directions:
The learner should read the learning objectives and study the publication. After analyzing the material, the learner should complete the Activity Self-assessment Test consisting of a series of multiple-choice questions.

Upon successfully completing this activity as designed and achieving a passing score of 70% or higher on the Activity Self-assessment Test, participants will receive a continuing education credit letter awarding the appropriate credit and the Activity Self-assessment Test answers four to six weeks after the receipt of the registration and evaluation materials.

Estimated time to complete this activity as designed is 1.5 hours.

CME Testing Options